Skip to Main Content

Paper Details

A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors.
Nat Cancer
166
2021
-, ATPase, BRCA, BRCA-deficient tumor, BRCA-deficient tumor cells, DNA polymerase theta, GEMM, HR, HR-deficient breast and ovarian tumors, HR-deficient cancers, HR-deficient tumor cells, HR-deficient tumors, Homologous, Homologous Recombination (HR) deficiency, Homologous-Recombination-Deficient Tumors, NVB, Novobiocin, PARP, PARPi, PARPi-resistant cells, POL, POL ATPase domain, Polymerase Theta, RAD51, resistant cells, single-strand DNA, xenograft
Author NameAffiliation
John A TainerUniversity of Texas MD Anderson Cancer Center
Alan D D'AndreaDana-Farber Cancer Institute, Harvard Medical School
Alan D D'AndreaCenter for DNA Damage and Repair, Dana-Farber Cancer Institute
Alan D D'AndreaSusan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute
Alan D D'AndreaDana-Farber Cancer Institute, Harvard Medical School
Alan D D'AndreaCenter for DNA Damage and Repair, Dana-Farber Cancer Institute
Alan D D'AndreaSusan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute
  • 1 - 7

Datasets

Release 1.2